Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (<scp>COMFORT</scp>‐1)

Piclidenoson demonstrated efficacy responses that increased over time alongside a favourable safety profile. These findings support its continued clinical development as a psoriasis treatment (ClinicalTrials.gov identifier: NCT03168256).